Loading...
•
Dec 31, 2023
Abbott Q4 2023 Earnings Report
Reported a sales increase and issued full-year guidance for diluted EPS and organic sales growth.
Key Takeaways
Abbott's Q4 2023 earnings showcased a 1.5% increase in reported sales, with organic sales growth for the underlying base business increasing by 11.0%. The company issued full-year 2024 guidance for diluted EPS on a GAAP basis of $3.20 to $3.40 and full-year adjusted diluted EPS of $4.50 to $4.70, projecting organic sales growth, excluding COVID-19 testing-related sales, to be in the range of 8.0% to 10.0%.
Fourth-quarter sales increased 1.5 percent on a reported basis, 2.1 percent on an organic basis, and 11.0 percent on an organic basis, excluding COVID-19 testing-related sales.
Fourth-quarter GAAP diluted EPS of $0.91 and adjusted diluted EPS of $1.19, which excludes specified items.
Abbott issues full-year 2024 guidance for diluted EPS on a GAAP basis of $3.20 to $3.40 and full-year adjusted diluted EPS of $4.50 to $4.70.
Abbott projects full-year 2024 organic sales growth, excluding COVID-19 testing-related sales, to be in the range of 8.0% to 10.0%.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Abbott projects full-year 2024 diluted earnings per share under GAAP of $3.20 to $3.40 and adjusted diluted earnings per share of $4.50 to $4.70. Abbott projects full-year 2024 organic sales growth, excluding COVID-19 testing-related sales, to be in the range of 8.0% to 10.0%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...